Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of sequential IMED-P/GDP-P versus IMED-P or GDP-P in early-stage extranodal NK/T-cell lymphoma
ChiCTR1800018734Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegaspargase, gemcitabine, cisplatin, dexamethasone, methotrexate and 2 more in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) (3 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 5-year overall survival. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
pegaspargasegemcitabinecisplatindexamethasonemethotrexate
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR1800018734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018734.